| HS Code | 991813 |
| Product Name | Fmoc-D-proline |
| Cas Number | 101555-63-3 |
| Molecular Formula | C20H19NO4 |
| Molecular Weight | 337.37 g/mol |
| Appearance | White to off-white powder |
| Melting Point | 207-209 °C |
| Optical Rotation | [α]D20 = -40.0° (c=1, CHCl3) |
| Purity | ≥98.0% (HPLC) |
| Storage Temperature | 2-8 °C |
| Solubility | Soluble in DMF, DMSO, chloroform |
As an accredited Fmoc-D-proline factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Fmoc-D-proline, 5 g, packaged in a sealed amber glass vial with tamper-evident cap and product label. |
| Container Loading (20′ FCL) | Fmoc-D-proline shipped in 20′ FCL, palletized, securely lashed, moisture-protected, and temperature-controlled to maintain stability. |
| Shipping | Fmoc-D-proline ships at ambient temperature in a sealed, light-protected container. It should be kept dry and away from strong oxidizing agents. Standard handling with gloves and eye protection is recommended. Include appropriate hazard documentation for safe courier transport. |
| Storage | Store Fmoc-D-proline in a tightly sealed container, protected from light and moisture. Keep refrigerated, ideally at –20°C, in a desiccator. Avoid repeated temperature fluctuations and exposure to air. Under these conditions, the compound remains stable for long-term use. |
| Shelf Life | Shelf life: 2–3 years when stored sealed, dry, and protected from light at 2–8°C. |
Fmoc-D-proline (MW 337.37 g/mol) is used directly in automated Fmoc solid-phase peptide synthesis (SPPS) for the manufacture of D-proline-containing peptide APIs. The protected amino acid is dissolved in DMF or NMP at 0.2–0.5 mol/L and activated by HATU, HBTU, PyBOP, or DIC/Oxyma at 0 °C–25 °C. For synthesis on Rink amide AM resin at 0.3–0.6 mmol/g loading, the first coupling of Fmoc-D-proline to the linker is usually run with 4 equiv amino acid relative to resin loading, 4 equiv HATU, and 8 equiv DIPEA in DMF for 20–40 min. The coupling is not considered complete until the Kaiser or TNBS test shows no free primary amine; for the secondary amine generated after deprotection of D-proline, the chloranil test is preferred. Deprotection with 20% piperidine in DMF for 10–20 min yields the free secondary amine and dibenzofulvene-piperidine adduct; the dibenzofulvene chromophore is monitored at 301 nm to confirm Fmoc removal and to calculate resin loading. The use of D-proline rather than L-proline alters the local backbone turn geometry; this is exploited in constrained peptide therapeutics where the D-configuration restricts β-turn conformations. In production, automated synthesizers such as the CEM Liberty Blue or Biotage Alstra are configured with nitrogen agitation and 20–90 min coupling cycles for hindered D-proline residues after deprotection. Fmoc-D-proline is stored desiccated at 2–8 °C, with pre-drying at 25 °C under vacuum before use when container integrity has been compromised.
Two processing conflicts are encountered in SPPS. First, the secondary amine of deprotected D-proline is sterically hindered; acylation by the incoming Fmoc-amino acid requires high-efficiency activation with COMU or HATU, otherwise deletion sequences accumulate as process impurities. Second, when Fmoc-D-proline is anchored as a C-terminal ester to Wang or 2-chlorotrityl chloride resin, the deprotection of the penultimate residue can generate diketopiperazine (DKP) and cleave the peptide from the resin. The DKP formation rate is sequence-dependent and increases in the presence of residual piperidine; draining is therefore performed with DMF washes after deprotection, and DCM shrinkage is avoided when DKP is suspected. Bulk resin loading after Fmoc-D-proline attachment is back-calculated from dibenzofulvene absorbance at 301 nm against a standard curve; values outside 0.2–0.6 mmol/g trigger re-coupling or resin capping with acetic anhydride/pyridine. Peptide production under GMP is governed by ICH Q7; critical process parameters for coupling, washing, and cleavage are recorded through an electronic batch record compliant with 21 CFR Part 11.
The terminal output is a crude peptide trifluoroacetate salt that is purified by preparative reversed-phase HPLC. Purified fractions are pooled at a purity threshold of 95% for toxicological material and 98–99% for late-stage API, then lyophilized. Final peptide content is determined by amino acid analysis; D-proline recovery after acid hydrolysis is corrected for slow proline release. The steric hindrance of D-proline and its position in the sequence are documented in the batch record because they influence the impurity profile during acidolytic cleavage with TFA/triisopropylsilane/water at 95:2.5:2.5.
Solution-phase assembly of protected peptide fragments begins with activation of the Fmoc-D-proline carboxyl function as a mixed anhydride. Fmoc-D-proline is dissolved in THF at 0.3–0.5 mol/L and treated with N-methylmorpholine and isobutyl chloroformate at −15 °C to 0 °C. The resulting mixed anhydride is stable only within a narrow thermal window; above 5 °C, decomposition through decarbonylation reduces active-species concentration and produces process impurities. The activated Fmoc-D-proline is coupled to a C-terminal peptide ester under Schotten-Baumann conditions, with pH maintained at 8.0–8.5 to keep the amine nucleophilic while avoiding premature Fmoc removal. Reaction monitoring is by TLC and HPLC; the Fmoc chromophore is followed at 254 nm, and disappearance of the free amine is confirmed by ninhydrin stain. After coupling, the protected fragment is extracted into ethyl acetate and washed against 5% citric acid and brine; residual THF is removed under reduced pressure at 35 °C–40 °C. The D-proline residue lowers Cα epimerization risk relative to open-chain amino acids because the pyrrolidine ring restricts enolate geometry; however, base strength and temperature remain critical because Fmoc removal by secondary amines accelerates above 25 °C. Residual ethyl acetate and THF are controlled under ICH Q3C, and the dried fragment is sampled for headspace GC before proceeding to deprotection.
At production scale, the main bottleneck is removal of the mixed-anhydride byproducts and excess base. Aqueous workup in a reactor with high interfacial tension can produce emulsions; the emulsion layer is broken with saturated sodium chloride or by standing at 4 °C for 2–4 h. Dicyclohexylurea from carbodiimide activation is not an issue when isobutyl chloroformate is used, which is why the mixed-anhydride route is preferred for moisture-sensitive fragments. The isolated Fmoc-D-proline-containing fragment is typically an oil or foam; it is stored under argon at −20 °C when not used within 24 h.
The Fmoc group on D-proline serves as an acid-labile N-protecting group during conversion of the carboxylic acid to chiral auxiliaries and organocatalysts. Fmoc-D-proline is coupled to amine-functionalized scaffolds by DCC/HOBt activation in DCM at 0–5 °C for 2–5 h. The Fmoc-protected intermediate is isolated by filtration of dicyclohexylurea, extraction against sodium bicarbonate and citric acid, and precipitation from cold MTBE/hexane. Fmoc removal is then carried out with 20% piperidine in DMF for 10–30 min; the liberated secondary amine is used to catalyze enantioselective aldol, Michael, or Mannich reactions after formulation as a free base or hydrochloride salt. The enantiomeric excess obtained with each auxiliary and electrophile is substrate-specific; published data for this specific configuration are limited, so pilot reactions are required before scale-up. Chiral HPLC or supercritical fluid chromatography is used to determine enantiomeric excess, with column selection based on the auxiliary structure; the system suitability criteria follow USP <621>.
The conversion of Fmoc-D-proline to a D-proline-derived auxiliary is sensitive to residual water in the activation solvent. DCM is pre-dried over 4 Å molecular sieves and stored under nitrogen; a Karl Fischer water content of ≤0.05% is preferred for the DCC/HOBt activation. If water is present, the O-acylisourea intermediate hydrolyzes before HOBt exchange, reducing the active ester concentration and producing Fmoc-D-proline that must be recovered from the aqueous phase. After Fmoc removal, the D-proline secondary amine is protonated with 1 M HCl in dioxane to give the hydrochloride salt, which is easier to handle than the free base because the free base can absorb CO₂ from air. The salt is dried under vacuum at 35 °C and stored desiccated.
Macrocyclic peptide candidates that incorporate D-proline as a reverse-turn element are frequently assembled with Fmoc-D-proline at the turn position. The protected amino acid is introduced on 2-chlorotrityl chloride resin via its carboxylate, using 1.5–3 equiv Fmoc-D-proline and 3–6 equiv DIPEA in DCM. After linear assembly, the C-terminal carboxyl is released selectively with 20% hexafluoroisopropanol in DCM or 1% TFA in DCM, leaving side-chain protecting groups intact. Cyclization is then performed in solution under pseudo-dilution, with peptide concentration controlled at 0.5–1 mmol/L and activation by HATU/DIPEA. The D-proline residue preorganizes the linear precursor into a bent conformation; however, macrocycles smaller than 15 residues can suffer from transannular strain and slow ring closure. Capillary HPLC and LC-MS are used to track cyclic monomer, linear precursor, and cyclodimer; the linear precursor often appears as the dominant impurity when cyclization is incomplete. Preparative reversed-phase HPLC is used for crude purification; pooled fractions are collected at a 95% purity threshold, then lyophilized to a moisture content below 3%. Residual trifluoroacetate is exchanged to acetate or hydrochloride by ion-exchange chromatography before final lyophilization. Production and cleaning validation are conducted under ICH Q7; peptide content and D-proline configuration are confirmed by amino acid analysis and chiral HPLC of the acid hydrolysate.
Continuous-flow SPPS changes the mass-transfer environment for Fmoc-D-proline coupling. In a heated packed-bed reactor, Fmoc-D-proline is pumped as a 0.4 M solution in DMF with HATU and DIPEA through a preactivation loop. The preactivation time is typically 30–90 s before the activated amino acid contacts the resin-bound free amine. Deprotection is performed with 20% piperidine in DMF at 0.2–0.5 mL/min; in-line UV detection at 301 nm continuously records dibenzofulvene generation. A drop in the 301 nm signal after deprotection indicates incomplete Fmoc removal or channeling in the packed bed. Coupling temperature is set between 60 °C and 80 °C, with a backpressure regulator maintaining 200–250 psi to prevent solvent boiling. The elevated temperature accelerates acylation of the hindered D-proline secondary amine; temperatures above 80 °C increase side reactions including premature Fmoc loss and rearrangement of activated ester to oxazolone. Continuous-flow operation reduces diketopiperazine risk because deprotection and coupling are separated by solvent wash segments, and the residence time is controlled by pump flow rate and reactor volume rather than manual draining. Resin loading and coupling efficiency are confirmed off-line by chloranil testing and on-line by UV integration. The flow reactor system is qualified under ICH Q7 for GMP production, and process analytical technology data are stored in accordance with 21 CFR Part 11.
Scale-out to multiple parallel reactors requires verification of identical backpressure, temperature, and UV path length; otherwise coupling efficiency shifts between reactor lines. Residence time distribution in packed-bed reactors is measured with a tracer, and channeling is identified by the asymmetry of the UV breakthrough front.
Incoming Fmoc-D-proline for GMP peptide production is released against a fixed analytical panel prior to use in manufacturing. Identity is confirmed by infrared absorption spectrophotometry according to Ph.Eur. 2.2.24 and by specific rotation against a qualified reference standard. Assay and related substances are determined by reversed-phase HPLC at 210–220 nm; research-grade material typically requires ≥99.0% area purity, while GMP starting material for peptide APIs requires ≥99.5%. Chiral purity is measured by chiral HPLC to control the L-proline enantiomer at not more than 0.5%. Water content is determined by Karl Fischer titration per USP <921> with an acceptance limit of ≤0.5% to avoid stoichiometry errors in automated synthesizers. Residual solvents from the Fmoc protection process—DMF, THF, dioxane, and ethyl acetate—are controlled under ICH Q3C, and elemental impurities are assessed under ICH Q3D. The release panel supports the use of Fmoc-D-proline as a starting material in peptide API manufacturing under ICH Q11, where the control strategy for the protected amino acid is linked to downstream peptide impurity profiles and residual solvent clearance.
| Quality attribute | Method | Acceptance control |
|---|---|---|
| Identification | IR absorption spectrophotometry Ph.Eur. 2.2.24 | Conforms to reference spectrum |
| Chiral purity | Chiral HPLC | L-proline enantiomer ≤ 0.5% |
| Assay | RP-HPLC at 210–220 nm | ≥ 99.0% research; ≥ 99.5% GMP |
| Water content | Karl Fischer titration USP <921> | ≤ 0.5% |
| Residual solvents | Headspace GC ICH Q3C | DMF, THF, dioxane, ethyl acetate reported |
| Elemental impurities | ICP-MS ICH Q3D | Option 1 limits |
Competitive Fmoc-D-proline prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Fmoc-D-proline, systematically named (2R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-carboxylic acid and assigned CAS 101555-62-8, is a protected chiral amino acid supplied as a white to off-white powder. The product has a molecular formula of C20H19NO4, a molar mass of 337.37 g/mol, and is referred to in synthesis workflows as N-α-Fmoc-D-proline or Fmoc-D-Pro-OH. The base-labile fluoren-9-ylmethoxycarbonyl group protects the secondary amine of D-proline and is removed selectively by secondary amines such as piperidine, while the free carboxylic acid remains available for activation and peptide bond formation. The material is used predominantly as a protected building block in Fmoc solid-phase peptide synthesis (SPPS), where the final sequence is assembled on acid-labile resins such as Wang, Rink amide, or 2-chlorotrityl chloride supports. Fmoc-D-proline is distinguished from Fmoc-L-proline only by the stereochemical configuration at Cα, but the two enantiomers share molecular formula, molar mass, and Fmoc chromophore while producing non-equivalent backbone chirality and conformational space when incorporated into a peptide chain.
Lot-specific release criteria vary by manufacturer, but the following profile is representative of research-grade material and should be confirmed against the certificate of analysis.
| Parameter | Typical specification | Analytical method |
|---|---|---|
| Systematic name | (2R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-carboxylic acid | Nomenclature |
| CAS registry number | CAS 101555-62-8 | — |
| Molecular formula | C20H19NO4 | Elemental analysis or HRMS |
| Molar mass | 337.37 g/mol | — |
| Appearance | White to off-white powder | Visual inspection |
| Purity | ≥98.0% or ≥99.0% | RP-HPLC with UV detection at 210–254 nm |
| Enantiomeric excess | ≥99.0% to ≥99.5% | Chiral HPLC or capillary electrophoresis |
| Storage temperature | −20 °C desiccated | Stability trial |
In Fmoc SPPS, activation of Fmoc-D-proline with aminium or carbodiimide reagents does not proceed through the oxazolone intermediate observed for N-acyl amino acids, because the proline nitrogen is fully substituted and the N-protecting group is a carbamate. This suppresses oxazolone-mediated racemization but also lowers the reactivity of the activated species relative to primary Fmoc-amino acids. Automated synthesizers with feedback-controlled microwave or induction heating therefore adopt higher molar excess, longer coupling times, or programmed double-coupling cycles when Fmoc-D-proline is the incoming residue. Practical protocols frequently specify 2.0 to 4.0 equivalents of activated Fmoc-D-proline relative to free resin amine, but the exact stoichiometry depends on resin loading, peptide length, and solvent viscosity. Activation with DIC/Oxyma in DMF typically requires shorter preactivation than carbodiimide/HOBt systems; systematic kinetic data for Fmoc-D-proline under all activation reagents is limited. Coupling completion is checked by ninhydrin or picric acid tests, and residual free amine is capped with acetic anhydride/pyridine before subsequent deprotection. On production-scale automated synthesizers with reaction vessels above 1 L, single-coupling of hindered proline residues can result in measurable des-proline deletion peptides; therefore a second coupling step or flow-through recirculation is often used.
Deletion impurities are the principal process risk when Fmoc-D-proline is coupled to hindered N-terminal residues. Incomplete coupling leaves a free amine that is capped in the next step, generating a truncated peptide that may be difficult to separate from the target by ion-exchange or reversed-phase methods. The Kaiser test is performed after coupling at 100 °C for 5 min for free amine detection; positive beads are recoupled before Fmoc removal. The picric acid test may be preferred for sequences containing proline linked through secondary amines because ninhydrin can give ambiguous colour responses with secondary amines. These analytical checks are especially relevant for D-proline because stereochemical inversion creates diastereomeric deletion products that can mimic the desired peptide in preparative chromatography.
Fmoc-D-proline is stored as a dry solid at −20 °C in tightly sealed amber glass containers under inert gas; short-term handling at 2–8 °C is acceptable if the container is closed and desiccated. The Fmoc group is removed by β-elimination in the presence of secondary amines, a pathway deliberately exploited with 20% piperidine in DMF during SPPS deprotection but a degradation route if the powder is exposed to amine vapours or alkaline reagents. Moisture absorption at ambient humidity can destabilise the carbamate; desiccation before storage and avoidance of repeated warming cycles are therefore required. For routine solution preparation, the free acid dissolves readily in DMF, dimethyl sulfoxide, and dichloromethane, while aqueous solubility at neutral pH is limited and usually requires addition of an organic cosolvent. Deprotection in solution or on resin releases dibenzofulvene, which forms a UV-active adduct detectable at 290–301 nm; this signal is used to monitor deprotection and resin loading on automated instruments. The product should not be stored in the same enclosure as open piperidine, morpholine, or dibutylamine containers.
The product must be brought to ambient temperature before weighing; opening a cold container in a humid room causes water condensation that can initiate slow carbamate cleavage. In automated SPPS, stock solutions in DMF are used within 24 h when held at 4 °C unless stability data support longer storage. Fmoc protection is substantially more acid-stable than Boc, but prolonged treatment with high concentrations of trifluoroacetic acid can gradually degrade the carbamate if residual Fmoc is left on the peptide. No formal open-vessel stability period at room temperature is established by pharmacopoeial monograph; therefore storage decisions should be based on internal forced-degradation data.
Absence of a dedicated chiral release method can compromise the diastereomeric purity of the assembled peptide because residual Fmoc-L-proline incorporation produces a product that may co-elute with the target sequence on reversed-phase purification. For this reason, Fmoc-D-proline quality control combines achiral RP-HPLC for organic purity with chiral HPLC or chiral capillary electrophoresis for enantiomeric excess. Chiral stationary phases based on amylose tris(3,5-dimethylphenylcarbamate) with hexane/alcohol mobile phases and trifluoroacetic acid modifier are suitable for many N-protected amino acids; alternative methods include derivatisation followed by gas chromatography. Research-grade material is commonly released with an enantiomeric excess of ≥99.0%, while higher grades used in regulated peptide manufacture may specify ≥99.5%. Residual solvent content is determined by headspace gas chromatography with flame ionisation detection, and the certificate of analysis should be checked for identity by infrared spectroscopy, water content, and heavy metal contamination before use in pharmaceutical development.
For critical applications, chiral purity can also be confirmed by hydrolysis of the Fmoc group followed by derivatisation with chiral reagents and gas chromatography-mass spectrometry. This approach separates the D- and L-proline derivatives and provides an orthogonal check on the HPLC result. However, the base used to remove Fmoc may induce a small amount of racemisation if conditions are too forcing; hydrolysis with dipolar aprotic solvent and controlled piperidine exposure is used to minimise artefacts.
For solution-phase activation, Fmoc-D-proline is converted to an active ester or mixed anhydride; water must be excluded from carbodiimide-mediated reactions to prevent rearrangement to N-acylurea. The fully substituted proline nitrogen can reduce aminolysis rates when the acylating species is crowded, and the use of catalytic 4-dimethylaminopyridine is limited by the risk of base-induced epimerisation. At pilot scale, precipitation of the dibenzofulvene-piperidine adduct during Fmoc removal can foul sintered filters and transfer lines if the deprotection solution cools below ambient temperature; the adduct remains soluble in warm DMF but may crystallise in cold solvents. Equipment cleaning therefore includes warm DMF rinses rather than solvent mixtures with high cyclohexane content, and published data on the exact precipitation threshold for this specific adduct in mixed solvents is limited.
Mixing and dissolution in peptide synthesis are more demanding when Fmoc-D-proline is used in N-methyl-2-pyrrolidone rather than DMF because the higher viscosity of N-methyl-2-pyrrolidone reduces mass transfer in solid-phase reactors. At laboratory scale, vortex or overhead stirring of the resin suspension is usually sufficient; in batch reactors above 500 mL, resin settling and poor mass transfer become rate-limiting unless the bottom filter is designed to avoid dead volume. The use of an inert atmosphere during coupling and deprotection minimises oxidation of tryptophan and methionine residues elsewhere in the sequence, but Fmoc-D-proline itself is not a strong oxidant or reducing agent.
The structural consequence of replacing L-proline with Fmoc-D-proline is inversion of the Cα stereocentre, not simply an increase in side-chain bulk. Proline’s five-membered pyrrolidine ring restricts backbone N–Cα rotation and lowers the barrier to cis peptide bond isomerisation for the preceding residue. The D configuration shifts the allowed φ and ψ angles and can favour type II’ β-turn geometry when placed at the i+1 position of a turn, although the exact geometry depends on sequence, solvent, and adjacent residues. Solution nuclear magnetic resonance studies show that Xaa-D-Pro sequences may exhibit a different cis/trans residue population than the corresponding Xaa-L-Pro sequences; published isomer ratios for individual peptides are compound-specific. Incorporation of D-proline into cyclic peptides and peptidomimetics is used to reduce conformational entropy penalties during target binding and to restrict backbone flexibility. Proteolytic stability of the resulting peptides is measured by incubation in plasma or enzyme assays with liquid chromatography-tandem mass spectrometry quantification; no universal numerical stability improvement is assignable because susceptibility depends on the protease and adjacent residues.
D-proline residues are introduced not only to tune secondary structure but also to alter global peptide hydrophilicity and to disrupt aggregation during solid-phase assembly. Peptide chains with multiple L-proline residues may associate through polyproline helices; insertion of D-proline can interrupt these interactions and improve resin solvation. The effect is sequence-dependent and is evaluated by analytical ultracentrifugation or size-exclusion chromatography during process development. Published formulation-level data for Fmoc-D-proline-containing peptide sequences is limited because aggregation is a function of the full sequence rather than the protected amino acid building block.
Product differentiation is clearest when Fmoc-D-proline is compared with Fmoc-L-proline and with Boc-D-proline. Fmoc and Boc groups provide orthogonal N-protection strategies: Fmoc is removed by bases such as piperidine or DBU, whereas Boc is removed by acids such as trifluoroacetic acid. The D-proline backbone remains identical in both protected forms, but the protecting group choice determines compatibility with the global protection scheme and final resin cleavage.
| Attribute | Fmoc-D-proline | Fmoc-L-proline | Boc-D-proline |
|---|---|---|---|
| CAS registry number | CAS 101555-62-8 | CAS 71989-31-6 | CAS 37784-17-1 |
| Cα configuration | R | S | R |
| Molecular formula | C20H19NO4 | C20H19NO4 | C10H17NO4 |
| Molar mass | 337.37 g/mol | 337.37 g/mol | 215.25 g/mol |
| N-protection removal | Base-labile | Base-labile | Acid-labile |
| Main synthetic use | Fmoc SPPS | Fmoc SPPS | Boc SPPS or solution phase |
Within the Fmoc-D-proline family, the free carboxylic acid is differentiated from methyl or tert-butyl ester derivatives by the carboxyl protecting state; Fmoc-D-Pro-OtBu is used when solution-phase selective ester hydrolysis is required, while Fmoc-D-Pro-OH is the standard SPPS intermediate. Resin-bound Fmoc-D-proline is also available for the generation of C-terminal proline peptides, but lot-specific loading values must be quantified before synthesis.
Research and manufacturing lots of Fmoc-D-proline are released with certificates of analysis that may be aligned to ISO 9001:2015 quality management systems, although the compound itself is not an approved drug substance and should not be cited against a pharmacopoeial monograph unless a specific monograph exists. Residual solvent analysis is usually performed by headspace gas chromatography with flame ionisation detection, with acceptance limits set according to ICH Q3C for solvents such as methanol, dichloromethane, ethyl acetate, and hexane. For peptide manufacturing under good manufacturing practice, the user must verify that the vendor’s analytical package includes identity by Fourier-transform infrared spectroscopy, chiral purity, residual solvents, and contamination information concerning heavy metals. Additional qualification may be required under ICH Q7 when the material is used in the manufacture of active pharmaceutical ingredients. Safety data sheets should be current and compliant with REACH or equivalent regional chemical regulations; the product is intended for research and further chemical processing, not for direct use as a pharmaceutical ingredient.
